Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Taragarestrant (D-0502) Formulations in Healthy Females
NCT05226338Phase 1Completed
- Sponsor
- InventisBio
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of taragarestrant in breast cancer (6 arms), sponsored by InventisBio. Primary endpoint: Oral bioavailability of D-0502 100mg and 200mg tablets at 42 days. Started Oct 2021; status: completed.
02
Drugs
taragarestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05226338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226338.